These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33522579)

  • 1. Neurokinin 3 Receptor Antagonism Ameliorates Key Metabolic Features in a Hyperandrogenic PCOS Mouse Model.
    Sucquart IE; Nagarkar R; Edwards MC; Rodriguez Paris V; Aflatounian A; Bertoldo MJ; Campbell RE; Gilchrist RB; Begg DP; Handelsman DJ; Padmanabhan V; Anderson RA; Walters KA
    Endocrinology; 2021 May; 162(5):. PubMed ID: 33522579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model.
    Xiong T; Rodriguez Paris V; Edwards MC; Hu Y; Cochran BJ; Rye KA; Ledger WL; Padmanabhan V; Handelsman DJ; Gilchrist RB; Walters KA
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E145-E158. PubMed ID: 35658542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Action in Adipose Tissue and the Brain are Key Mediators in the Development of PCOS Traits in a Mouse Model.
    Cox MJ; Edwards MC; Rodriguez Paris V; Aflatounian A; Ledger WL; Gilchrist RB; Padmanabhan V; Handelsman DJ; Walters KA
    Endocrinology; 2020 Jul; 161(7):. PubMed ID: 32301482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The overexpression of neurokinin B-neurokinin 3 receptor system exerts direct effects on the ovary under PCOS-like conditions to interfere with mitochondrial function.
    Guo F; Fernando T; Zhu X; Shi Y
    Am J Reprod Immunol; 2023 Mar; 89(3):e13663. PubMed ID: 36453600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model.
    Aflatounian A; Edwards MC; Rodriguez Paris V; Bertoldo MJ; Desai R; Gilchrist RB; Ledger WL; Handelsman DJ; Walters KA
    J Endocrinol; 2020 Jun; 245(3):381-395. PubMed ID: 32229702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization.
    Caldwell AS; Eid S; Kay CR; Jimenez M; McMahon AC; Desai R; Allan CM; Smith JT; Handelsman DJ; Walters KA
    Endocrinology; 2015 Apr; 156(4):1441-52. PubMed ID: 25643156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurokinin 3 receptor antagonist-induced adipocyte activation improves obesity and metabolism in PCOS-like mice.
    Zhang L; Fernando T; Liu Y; Liu Y; Zhu X; Li M; Shi Y
    Life Sci; 2022 Dec; 310():121078. PubMed ID: 36252700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of the kisspeptin/KISS1R and neurokinin B/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome.
    Blasco V; Pinto FM; Fernández-Atucha A; Prados N; Tena-Sempere M; Fernández-Sánchez M; Candenas L
    J Assist Reprod Genet; 2019 Jan; 36(1):113-120. PubMed ID: 30382469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-21 modulates brown adipose tissue adipogenesis and thermogenesis in a mouse model of polycystic ovary syndrome.
    Rezq S; Huffman AM; Basnet J; Alsemeh AE; do Carmo JM; Yanes Cardozo LL; Romero DG
    Biol Sex Differ; 2024 Jul; 15(1):53. PubMed ID: 38987854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of Androgen Receptors From Kisspeptin Neurons Prevents PCOS Features in a Letrozole Mouse Model.
    Decourt C; Watanabe Y; Evans MC; Inglis MA; Fisher LC; Jasoni CL; Campbell RE; Anderson GM
    Endocrinology; 2023 Apr; 164(6):. PubMed ID: 37191144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating GABA Neuron-Specific Androgen Receptor Knockout in two Hyperandrogenic Models of PCOS.
    Sucquart IE; Coyle C; Rodriguez Paris V; Prescott M; Glendining KA; Potapov K; Begg DP; Gilchrist RB; Walters KA; Campbell RE
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38788194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Removal of DHT can relieve polycystic ovarian but not metabolic abnormalities in DHT-induced hyperandrogenism in mice.
    Sun LF; Yang YL; Xiao TX; Li MX; Zhang JV
    Reprod Fertil Dev; 2019 Sep; 31(10):1597-1606. PubMed ID: 31142430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
    Caldwell ASL; Edwards MC; Desai R; Jimenez M; Gilchrist RB; Handelsman DJ; Walters KA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):E3334-E3343. PubMed ID: 28320971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
    Arroyo P; Ho BS; Sau L; Kelley ST; Thackray VG
    PLoS One; 2019; 14(9):e0223274. PubMed ID: 31568518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of DHT-Induced Hyperandrogenism on the Pro-Inflammatory Cytokines in a Rat Model of Polycystic Ovary Morphology.
    Krishnan A; Muthusami S; Periyasamy L; Stanley JA; Gopalakrishnan V; Ramachandran I
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32120970
    [No Abstract]   [Full Text] [Related]  

  • 17. The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse.
    Ji SY; Liu XM; Li BT; Zhang YL; Liu HB; Zhang YC; Chen ZJ; Liu J; Fan HY
    Mol Hum Reprod; 2017 Oct; 23(10):698-707. PubMed ID: 28961951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS).
    Garg A; Patel B; Abbara A; Dhillo WS
    Clin Endocrinol (Oxf); 2022 Aug; 97(2):156-164. PubMed ID: 35262967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive and metabolic phenotype of a mouse model of PCOS.
    van Houten EL; Kramer P; McLuskey A; Karels B; Themmen AP; Visser JA
    Endocrinology; 2012 Jun; 153(6):2861-9. PubMed ID: 22334715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.